Zinzino Group has reported an impressive 60% increase in revenue for the first quarter of 2025, marking a major milestone in the company’s global growth journey. Total group revenue reached SEK 725.9 million (USD $454.5 million), up from SEK 454.5 million in Q1 2024.
Zinzino’s March 2025 sales grew by 79%, totaling SEK 268.0 million (USD $149.7 million).
Faun Pharma, a Zinzino subsidiary, reported external sales of SEK 7.1 million (USD $9.8 million).
Total Q1 2025 Group revenue: SEK 725.9 million (USD $454.5 million), a 60% increase YoY.
Asia-Pacific led the surge with a 427% increase in Q1 revenue.
North America followed with a 217% rise.
Strong growth was also seen in South & West Europe (+79%) and Central Europe (+66%).
The Nordics: +13%
Central Europe: +66%
East Europe: +4%
South & West Europe: +79%
The Baltics: +21%
North America: +217%
Asia-Pacific: +427%
Africa: +55%
Despite a 42% decline in Faun Pharma sales, the group’s performance remained strong, driven by Zinzino’s personalized nutrition and wellness solutions.
Zinzino is a Scandinavian direct sales company specializing in test-based, personalized nutrition and scientific skincare. The company operates in over 100 global markets and is listed on Nasdaq First North Premier. Its portfolio includes BioActive Foods, Faun Pharma, and Swiss skincare brand HANZZ+HEIDII.
There are no reviews yet. Be the first one to write one.
